We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

26 hedge funds and large institutions have $198M invested in CRISPR Therapeutics in 2016 Q4 according to their latest regulatory filings, with 26 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

24.7% more ownership

Funds ownership: 0% → 24.7% (+25%)

Holders
26
Holders Change
+26
Holders Change %
–
% of All Funds
0.65%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.1%
New
26
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
+$60.2M
2
A
Abingworth
United Kingdom
+$48.6M
3
CCP
Clough Capital Partners
Massachusetts
+$15.7M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$13.9M
5
Franklin Resources
Franklin Resources
California
+$13.6M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$65.3M +$60.2M +3,220,728 New
A
2
Abingworth
United Kingdom
$52M +$48.6M +2,601,814 New
CCP
3
Clough Capital Partners
Massachusetts
$16.7M +$15.7M +838,791 New
Wellington Management Group
4
Wellington Management Group
Massachusetts
$15M +$13.9M +744,380 New
Franklin Resources
5
Franklin Resources
California
$14.4M +$13.6M +729,333 New
NLVP
6
New Leaf Venture Partners
New York
$11.9M +$11M +586,475 New
O
7
OrbiMed
New York
$7.54M +$6.96M +372,191 New
NHAS
8
Novo Holdings A/S
Denmark
$4.52M +$4.17M +223,317 New
Lord, Abbett & Co
9
Lord, Abbett & Co
New Jersey
$4.29M +$3.96M +211,700 New
VC
10
Vivo Capital
California
$3.02M +$2.78M +148,878 New
JCG
11
JHL Capital Group
Illinois
$1.22M +$1.12M +60,000 New
LCM
12
Laurion Capital Management
New York
$527K +$486K +26,000 New
Bank of America
13
Bank of America
North Carolina
$436K +$402K +21,500 New
Geode Capital Management
14
Geode Capital Management
Massachusetts
$371K +$343K +18,350 New
Millennium Management
15
Millennium Management
New York
$241K +$223K +11,913 New
MIM
16
Monashee Investment Management
Massachusetts
$146K +$134K +7,186 New
UBS Group
17
UBS Group
Switzerland
$82K +$75.5K +4,042 New
Morgan Stanley
18
Morgan Stanley
New York
$77K +$71.3K +3,816 New
Wells Fargo
19
Wells Fargo
California
$20K +$18.3K +980 New
SIC
20
Salem Investment Counselors
North Carolina
$13K +$12.1K +650 New
LWCFA
21
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$12K +$11.2K +600 New
TRCT
22
Tower Research Capital (TRC)
New York
$10K +$8.95K +479 New
IP
23
Intellectus Partners
California
$7K +$6.07K +325 New
ECM
24
Elgethun Capital Management
South Dakota
$6K +$5.61K +300 New
CCM
25
Cribstone Capital Management
Maine
$2K +$1.68K +90 New
1
2

CRSP Hedge Fund Activity: Q4 2016 in Review

26 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q4 2016, worth a combined $198M.

Buyers outnumbered sellers: 26 funds opened new CRSP positions and 0 closed out — a net gain of 26 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was NEA Management Company, opening a new position worth an estimated $60.2M.

  • 26 institutional investors held CRISPR Therapeutics (CRSP) as of Q4 2016, up from 0 in Q3 2016.
  • Funds reported $198M of CRISPR Therapeutics stock for Q4 2016.
  • 26 funds opened new CRISPR Therapeutics positions in Q4 2016 and 0 closed out, a net change of +26 holders.
  • The largest CRISPR Therapeutics buyer in Q4 2016 was NEA Management Company, an estimated $60.2M added.

Based on aggregated 13F filings for Q4 2016.